metformin has been researched along with Adenoma in 25 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Adenoma: A benign epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Metformin use was negatively associated with the incidence of colorectal adenoma (RR: 0." | 9.05 | Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. ( Deng, M; Huang, D; Lei, S; Wang, H; Wu, Y; Xia, S; Xu, E; Zhang, H, 2020) |
| "This meta-analysis showed that metformin use significantly reduces colorectal adenoma and cancer incidence and improves colorectal cancer outcomes." | 9.05 | Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. ( Chong, CS; Jiang, AA; Khoo, CM; Ng, CH; Ng, CW; Ong, ZH; Peng, S; Sundar, R; Tham, HY; Toh, EMS, 2020) |
| "Although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma." | 8.95 | Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis. ( Eun, CS; Han, DS; Jung, YS; Park, CH; Park, DI, 2017) |
| "Existing data evaluating the impact of metformin on the colorectal adenoma (CRA) risk in patients suffering from type 2 diabetes (T2D) are limited and controversial." | 8.95 | Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis. ( Fang, JY; Hou, YC; Hu, Q; Huang, J; Xiong, H, 2017) |
| "Recent evidence indicates that metformin therapy may be associated with a decreased colorectal adenoma/colorectal cancer risk in type 2 diabetes patients." | 8.95 | Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. ( Chu, Y; Li, X; Liu, F; Liu, Y; Lu, Y; Nie, S; Rui, D; Wang, Z; Xiang, H; Yan, L, 2017) |
| "We aimed to determine the impact of metformin use on the behavior of colorectal adenomas in a US veteran population." | 8.12 | Metformin Use Is Inversely Associated with Prevalent, but Not Incident Colorectal Adenomas. ( Abrams, JA; Araujo, JL; Buitrago, C; Huang, CH; Karkenny, G; Krigel, A; Lebwohl, B; Nguyen, STT; Talukder, N, 2022) |
| "Existing studies suggest that metformin lowers the risk and mortality of colorectal cancer." | 7.85 | The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. ( Cheon, JH; Han, MS; Hong, SP; Kim, TI; Kim, WH; Lee, HJ; Park, SJ, 2017) |
| "Existing literature suggests that metformin, the most commonly used biguanide, may lower colorectal cancer risk." | 7.81 | Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. ( Corley, DA; Doubeni, CA; Jensen, CD; Marks, AR; Pietrofesa, RA; Zebrowski, A, 2015) |
| "Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin." | 7.78 | Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012) |
| "Metformin has a potential role in the chemoprevention of colorectal cancer." | 6.82 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. ( Arimoto, J; Hata, Y; Hattori, A; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Komiya, Y; Matsuhashi, N; Nagase, H; Nakajima, A; Sakai, E; Taguri, M; Takahashi, H; Taniguchi, L; Uchiyama, S; Uchiyama, T; Umezawa, S; Yamanaka, S, 2016) |
| "Metformin is an old, inexpensive, and relatively safe anti-diabetic medication that can decrease the risk of several types of cancer in patients with diabetes." | 5.72 | The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. ( Ala, M, 2022) |
| "Metformin is an anti-hyperglycemic agent used to treat diabetes, and recent evidence suggests it has antitumor efficacy." | 5.46 | Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. ( An, J; Duan, L; He, J; Hu, J; Li, S; Pei, X; Shen, R; Yang, H; Zang, Z; Zhang, W; Zhang, Y; Zheng, X; Zhou, Z; Zhu, F, 2017) |
| " Metformin use was negatively associated with the incidence of colorectal adenoma (RR: 0." | 5.05 | Suppressive effects of metformin on colorectal adenoma incidence and malignant progression. ( Deng, M; Huang, D; Lei, S; Wang, H; Wu, Y; Xia, S; Xu, E; Zhang, H, 2020) |
| "This meta-analysis showed that metformin use significantly reduces colorectal adenoma and cancer incidence and improves colorectal cancer outcomes." | 5.05 | Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression. ( Chong, CS; Jiang, AA; Khoo, CM; Ng, CH; Ng, CW; Ong, ZH; Peng, S; Sundar, R; Tham, HY; Toh, EMS, 2020) |
| "Although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma." | 4.95 | Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis. ( Eun, CS; Han, DS; Jung, YS; Park, CH; Park, DI, 2017) |
| "Existing data evaluating the impact of metformin on the colorectal adenoma (CRA) risk in patients suffering from type 2 diabetes (T2D) are limited and controversial." | 4.95 | Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis. ( Fang, JY; Hou, YC; Hu, Q; Huang, J; Xiong, H, 2017) |
| "Recent evidence indicates that metformin therapy may be associated with a decreased colorectal adenoma/colorectal cancer risk in type 2 diabetes patients." | 4.95 | Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. ( Chu, Y; Li, X; Liu, F; Liu, Y; Lu, Y; Nie, S; Rui, D; Wang, Z; Xiang, H; Yan, L, 2017) |
| "We aimed to determine the impact of metformin use on the behavior of colorectal adenomas in a US veteran population." | 4.12 | Metformin Use Is Inversely Associated with Prevalent, but Not Incident Colorectal Adenomas. ( Abrams, JA; Araujo, JL; Buitrago, C; Huang, CH; Karkenny, G; Krigel, A; Lebwohl, B; Nguyen, STT; Talukder, N, 2022) |
| "Existing studies suggest that metformin lowers the risk and mortality of colorectal cancer." | 3.85 | The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma. ( Cheon, JH; Han, MS; Hong, SP; Kim, TI; Kim, WH; Lee, HJ; Park, SJ, 2017) |
| "Existing literature suggests that metformin, the most commonly used biguanide, may lower colorectal cancer risk." | 3.81 | Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus. ( Corley, DA; Doubeni, CA; Jensen, CD; Marks, AR; Pietrofesa, RA; Zebrowski, A, 2015) |
| "Among 488 consecutive diabetic patients who underwent colonoscopic surveillance after curative resection of colorectal cancer between 1998 and 2008, 240 patients were enrolled in this study and were compared in two groups: 114 patients taking metformin and 126 patients not taking metformin." | 3.78 | Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012) |
| "85 g metformin daily for 75 days, urinary retention caused by a prostatic adenoma induced functional renal insufficiency and hyperlactacidemia, rapidly reversed with treatment." | 3.66 | [Reversible lactic acidosis in a diabetic on high dose metformin (author's transl)]. ( Beaudot, C; Brohon, J; Lavieuville, M; Merceron, RE; Noël, M; Raymond, JP, 1980) |
| "Metformin has a potential role in the chemoprevention of colorectal cancer." | 2.82 | Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. ( Arimoto, J; Hata, Y; Hattori, A; Higurashi, T; Hosono, K; Inayama, Y; Kessoku, T; Komiya, Y; Matsuhashi, N; Nagase, H; Nakajima, A; Sakai, E; Taguri, M; Takahashi, H; Taniguchi, L; Uchiyama, S; Uchiyama, T; Umezawa, S; Yamanaka, S, 2016) |
| "Metformin is an old, inexpensive, and relatively safe anti-diabetic medication that can decrease the risk of several types of cancer in patients with diabetes." | 1.72 | The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer. ( Ala, M, 2022) |
| "Diabetic ketoacidosis has been described as a rare complication of acromegaly and may be observed in 1% of affected patients." | 1.46 | Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly. ( Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D, 2017) |
| "Metformin is an anti-hyperglycemic agent used to treat diabetes, and recent evidence suggests it has antitumor efficacy." | 1.46 | Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells. ( An, J; Duan, L; He, J; Hu, J; Li, S; Pei, X; Shen, R; Yang, H; Zang, Z; Zhang, W; Zhang, Y; Zheng, X; Zhou, Z; Zhu, F, 2017) |
| "Treatment with metformin alone and in combination with pioglitazone resulted in statistically significant decreases in lung adenoma formation at both early- and late-stage interventions." | 1.46 | Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention. ( Antonides, JD; Clapper, ML; Galbraith, AR; Haynes, AM; Miller, KA; Miller, MS; Miller, WA; O'Sullivan, MG; Ondrey, FG; Seabloom, DE; Steele, VE; Wuertz, BR, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 7 (28.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ala, M | 1 |
| Krigel, A | 1 |
| Nguyen, STT | 1 |
| Talukder, N | 1 |
| Huang, CH | 1 |
| Buitrago, C | 1 |
| Karkenny, G | 1 |
| Lebwohl, B | 1 |
| Abrams, JA | 1 |
| Araujo, JL | 1 |
| Zaccari, P | 1 |
| Archibugi, L | 1 |
| Belfiori, G | 1 |
| Nista, E | 1 |
| dell'Anna, G | 1 |
| Crippa, S | 1 |
| Schepis, T | 1 |
| Tacelli, M | 1 |
| Aleotti, F | 1 |
| Petrone, MC | 1 |
| Mariani, A | 1 |
| Costamagna, G | 1 |
| Gasbarrini, A | 1 |
| Larghi, A | 1 |
| Falconi, M | 1 |
| Arcidiacono, PG | 1 |
| Capurso, G | 1 |
| Elton, AC | 1 |
| Cedarstrom, V | 1 |
| Quraishi, A | 1 |
| Wuertz, B | 1 |
| Murray, K | 1 |
| Markowski, TW | 1 |
| Seabloom, D | 1 |
| Ondrey, FG | 2 |
| Luo, Z | 1 |
| Wang, B | 1 |
| Luo, F | 1 |
| Guo, Y | 1 |
| Jiang, N | 1 |
| Wei, J | 1 |
| Wang, X | 1 |
| Tseng, Y | 1 |
| Chen, J | 1 |
| Zhao, B | 1 |
| Liu, J | 1 |
| Deng, M | 1 |
| Lei, S | 1 |
| Huang, D | 1 |
| Wang, H | 1 |
| Xia, S | 1 |
| Xu, E | 1 |
| Wu, Y | 1 |
| Zhang, H | 1 |
| Ng, CW | 1 |
| Jiang, AA | 1 |
| Toh, EMS | 1 |
| Ng, CH | 1 |
| Ong, ZH | 1 |
| Peng, S | 1 |
| Tham, HY | 1 |
| Sundar, R | 1 |
| Chong, CS | 1 |
| Khoo, CM | 1 |
| Quarella, M | 1 |
| Walser, D | 1 |
| Brändle, M | 1 |
| Fournier, JY | 1 |
| Bilz, S | 1 |
| An, J | 1 |
| Pei, X | 1 |
| Zang, Z | 1 |
| Zhou, Z | 1 |
| Hu, J | 1 |
| Zheng, X | 1 |
| Zhang, Y | 1 |
| He, J | 1 |
| Duan, L | 1 |
| Shen, R | 1 |
| Zhang, W | 1 |
| Zhu, F | 1 |
| Li, S | 1 |
| Yang, H | 1 |
| Jung, YS | 1 |
| Park, CH | 1 |
| Eun, CS | 1 |
| Park, DI | 1 |
| Han, DS | 1 |
| Popovich, IG | 1 |
| Piskunova, TS | 1 |
| Tyndyk, ML | 1 |
| Anikin, IV | 1 |
| Zabezhinskiĭ, MA | 1 |
| Anisimov, VN | 1 |
| Kuo, SF | 1 |
| Chuang, WY | 1 |
| Ng, S | 1 |
| Chen, CH | 1 |
| Chang, CN | 1 |
| Chou, CH | 1 |
| Weng, WC | 1 |
| Yeh, CH | 1 |
| Lin, JD | 1 |
| Principi, M | 1 |
| De Censi, A | 1 |
| Gravitz, L | 1 |
| Marks, AR | 1 |
| Pietrofesa, RA | 1 |
| Jensen, CD | 1 |
| Zebrowski, A | 1 |
| Corley, DA | 1 |
| Doubeni, CA | 1 |
| Higurashi, T | 1 |
| Hosono, K | 2 |
| Takahashi, H | 2 |
| Komiya, Y | 1 |
| Umezawa, S | 1 |
| Sakai, E | 2 |
| Uchiyama, T | 2 |
| Taniguchi, L | 1 |
| Hata, Y | 1 |
| Uchiyama, S | 1 |
| Hattori, A | 1 |
| Nagase, H | 1 |
| Kessoku, T | 1 |
| Arimoto, J | 1 |
| Matsuhashi, N | 1 |
| Inayama, Y | 1 |
| Yamanaka, S | 1 |
| Taguri, M | 1 |
| Nakajima, A | 2 |
| Jain, D | 1 |
| Chhoda, A | 1 |
| Uribe, J | 1 |
| Hou, YC | 1 |
| Hu, Q | 1 |
| Huang, J | 1 |
| Fang, JY | 1 |
| Xiong, H | 1 |
| Liu, F | 1 |
| Yan, L | 1 |
| Wang, Z | 1 |
| Lu, Y | 1 |
| Chu, Y | 1 |
| Li, X | 1 |
| Liu, Y | 1 |
| Rui, D | 1 |
| Nie, S | 1 |
| Xiang, H | 1 |
| Seabloom, DE | 1 |
| Galbraith, AR | 1 |
| Haynes, AM | 1 |
| Antonides, JD | 1 |
| Wuertz, BR | 1 |
| Miller, WA | 1 |
| Miller, KA | 1 |
| Steele, VE | 1 |
| Miller, MS | 1 |
| Clapper, ML | 1 |
| O'Sullivan, MG | 1 |
| Han, MS | 1 |
| Lee, HJ | 1 |
| Park, SJ | 1 |
| Hong, SP | 2 |
| Cheon, JH | 2 |
| Kim, WH | 2 |
| Kim, TI | 2 |
| Endo, H | 1 |
| Sugiyama, M | 1 |
| Suzuki, K | 1 |
| Iida, H | 1 |
| Sakamoto, Y | 1 |
| Yoneda, K | 1 |
| Koide, T | 1 |
| Tokoro, C | 1 |
| Abe, Y | 1 |
| Inamori, M | 1 |
| Nakagama, H | 1 |
| Lee, JH | 1 |
| Jeon, SM | 1 |
| Ali, O | 1 |
| Banerjee, S | 1 |
| Kelly, DF | 1 |
| Lee, PD | 1 |
| Beaudot, C | 1 |
| Merceron, RE | 1 |
| Lavieuville, M | 1 |
| Noël, M | 1 |
| Brohon, J | 1 |
| Raymond, JP | 1 |
5 reviews available for metformin and Adenoma
| Article | Year |
|---|---|
Suppressive effects of metformin on colorectal adenoma incidence and malignant progression.
Topics: Adenoma; Asian People; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Disease Progression; Humans; | 2020 |
Metformin and colorectal cancer: a systematic review, meta-analysis and meta-regression.
Topics: Adenoma; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2020 |
Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis.
Topics: Adenoma; Colorectal Neoplasms; Databases, Bibliographic; Diabetes Complications; Diabetes Mellitus; | 2017 |
Metformin therapy and the risk of colorectal adenoma in patients with type 2 diabetes: A meta-analysis.
Topics: Adenoma; Aged; Chi-Square Distribution; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Female; Hum | 2017 |
Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis.
Topics: Adenoma; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Humans; Metformin | 2017 |
2 trials available for metformin and Adenoma
| Article | Year |
|---|---|
Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Chemoprevention; Colonic Polyps; Colonoscopy; Colorectal Ne | 2016 |
Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial.
Topics: Aberrant Crypt Foci; Adenoma; Aged; Antineoplastic Agents; Cell Proliferation; Clinical Trials as To | 2010 |
18 other studies available for metformin and Adenoma
| Article | Year |
|---|---|
The Emerging Role of Metformin in the Prevention and Treatment of Colorectal Cancer: A Game Changer for the Management of Colorectal Cancer.
Topics: Adenoma; Colorectal Neoplasms; Fluorouracil; Humans; Hypoglycemic Agents; Incidence; Metformin | 2022 |
Metformin Use Is Inversely Associated with Prevalent, but Not Incident Colorectal Adenomas.
Topics: Adenoma; Colonic Polyps; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Humans; Metfo | 2022 |
Risk factors for the occurrence of ampullary tumors: A case-control study.
Topics: Adenoma; Ampulla of Vater; Aspirin; Carcinoma; Case-Control Studies; Common Bile Duct Neoplasms; Duo | 2022 |
Metabolic and Metabolomic Effects of Metformin in Murine Model of Pulmonary Adenoma Formation.
Topics: Adenoma; Animals; Disease Models, Animal; Lung Neoplasms; Metformin; Mice; Weight Gain | 2023 |
Establishment of a large-scale patient-derived high-risk colorectal adenoma organoid biobank for high-throughput and high-content drug screening.
Topics: Adenoma; Biological Specimen Banks; Colorectal Neoplasms; Drug Evaluation, Preclinical; Humans; Metf | 2023 |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combi | 2017 |
Metformin inhibits proliferation and growth hormone secretion of GH3 pituitary adenoma cells.
Topics: Activating Transcription Factor 3; Adenoma; Adult; Aged; Animals; Cell Line, Tumor; Cell Proliferati | 2017 |
[Metformin effect on urethane-induced tumorigenesis in mice].
Topics: Adenoma; Administration, Oral; Animals; Anticarcinogenic Agents; Carcinogens; Cell Transformation, N | 2012 |
Pituitary gigantism presenting with depressive mood disorder and diabetic ketoacidosis in an Asian adolescent.
Topics: Adenoma; Adolescent; Adolescent Development; Antineoplastic Agents, Hormonal; Combined Modality Ther | 2013 |
Prevention of colorectal adenomas.
Topics: Adenoma; Aspirin; Colorectal Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Humans; Lig | 2015 |
Prevention: Tending the gut.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Cancer Vaccines; Clinical Trials as Topic; Colonic | 2015 |
Metformin use and risk of colorectal adenoma after polypectomy in patients with type 2 diabetes mellitus.
Topics: Adenoma; Adult; Aged; Aged, 80 and over; Colon; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Fem | 2015 |
Effect of Insulin and Metformin Combination Treatment on Colon Adenoma and Advanced Adenoma Among DM II.
Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabetes Complication | 2016 |
Fixed-Dose Combinations of Pioglitazone and Metformin for Lung Cancer Prevention.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Dose-Response Rel | 2017 |
The effect of metformin on the recurrence of colorectal adenoma in diabetic patients with previous colorectal adenoma.
Topics: Adenoma; Colorectal Neoplasms; Diabetes Mellitus; Female; Humans; Male; Metformin; Neoplasm Recurren | 2017 |
Metformin use is associated with a decreased incidence of colorectal adenomas in diabetic patients with previous colorectal cancer.
Topics: Adenoma; Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Colonoscopy; Colorectal Neoplasms; Diab | 2012 |
Management of type 2 diabetes mellitus associated with pituitary gigantism.
Topics: Adenoma; Adolescent; Antineoplastic Agents; Cabergoline; Combined Modality Therapy; Diabetes Mellitu | 2007 |
[Reversible lactic acidosis in a diabetic on high dose metformin (author's transl)].
Topics: Adenoma; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Humans; Lactates; Male; M | 1980 |